Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model.
暂无分享,去创建一个
J. Mayoral | V. Polo | J. Ruberte | E. Garcia-Martin | E. Vispe | J. Fraile | S. Méndez-Martínez | M. Rodrigo | M. Subías | T. Martínez-Rincón | M. J. Cardiel | C. Luna | T. Ramirez